INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment

M. J. Brown, A. Castaigne, L. M. Ruilope, G. Mancia, T. Rosenthal, P. W. De Leeuw, F. Ebner

Research output: Contribution to journalArticle

Abstract

The objective of the study is to compare fatal and nonfatal cardiovascular endpoints in hypertensive patients randomised to the calcium-channel blocker, nifedipine GITS or a thiazide diuretic, co-amilozide. A total of 6592 patients from nine countries (UK, France, Israel, Spain, Italy, The Netherlands, Sweden, Denmark and Norway) will be recruited, aged 55-80 and with a blood pressure (BP) ≤ 150/95 or ≤ 160 mmHg (systolic). All patients will have at least one other major cardiovascular risk factor. Patients will be minimised by country and risk factors and randomised to double-blind treatment with either nifedipine GITS or diuretic. After a single dose titration, additional treatment will be atenolol or enalapril (where P-blockade is contra-indicated). After achieving a target BP of 140/90 mmHg patients will be followed for a total of 3 years. Primary endpoints are myocardial infarction, stroke, subarachnoid haemorrhage, heart failure and sudden cardiac death. The study has a power of 80% at 5% significance to detect a difference between 8% event rate over 3 years in diuretic-treated patients and 6% in those receiving nifedipine.

Original languageEnglish
JournalJournal of Human Hypertension
Volume10
Issue numberSUPPL. 3
Publication statusPublished - 1996

Keywords

  • Morbidity
  • Mortality
  • Nifedipine
  • Outcome trial
  • Thiazide

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment'. Together they form a unique fingerprint.

  • Cite this

    Brown, M. J., Castaigne, A., Ruilope, L. M., Mancia, G., Rosenthal, T., De Leeuw, P. W., & Ebner, F. (1996). INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment. Journal of Human Hypertension, 10(SUPPL. 3).